Amdiglurax

Amdiglurax (NSI-189) is an orally active chemical entity with enhanced neurogenic activity. Amdiglurax up-regulates neurogenic factors such as BDNF (brain derived-neurotrophic factor) and SCF. Amdiglurax exhibits anti-depressant effect. Amdiglurax enhances synaptic plasticity and reduces cognitive dysfunction. Amdiglurax holds potential for psychiatric disorder research[1][2][3].

Product Specifications

CAS Number

[1270138-40-3]

Product Name Alternative

NSI-189

UNSPSC

12352005

Hazard Statement

H302

Target

Trk Receptor

Type

Reference compound

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nsi-189.html

Purity

99.57

Solubility

10 mM in DMSO|DMSO : 110 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(CC2=CC=CC=C2)CC1)C3=CC=CN=C3NCCC(C)C

Molecular Formula

C22H30N4O

Molecular Weight

366.50

Precautions

H302

References & Citations

[1]McIntyre RS, et al. The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects. Expert Opin Investig Drugs. 2017 Jun;26 (6) :767-770. |[2]Tajiri N, et al. NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats. J Cell Physiol. 2017 Oct;232 (10) :2731-2740. |[3]Jolivalt CG, et al. Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189. Diabetes. 2019 Nov;68 (11) :2143-2154.